HUE031370T2 - Eljárás 3,4-dimetoxibiciklo[4.2.0]okta-l,3,5-trién-7-karbonitril elõállítására, ennek alkalmazása ivabradine szintézisében, továbbá ennek gyógyszerészetileg elfogadható savval alkotott addíciós sója - Google Patents
Eljárás 3,4-dimetoxibiciklo[4.2.0]okta-l,3,5-trién-7-karbonitril elõállítására, ennek alkalmazása ivabradine szintézisében, továbbá ennek gyógyszerészetileg elfogadható savval alkotott addíciós sója Download PDFInfo
- Publication number
- HUE031370T2 HUE031370T2 HUE14168559A HUE14168559A HUE031370T2 HU E031370 T2 HUE031370 T2 HU E031370T2 HU E14168559 A HUE14168559 A HU E14168559A HU E14168559 A HUE14168559 A HU E14168559A HU E031370 T2 HUE031370 T2 HU E031370T2
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- eljárás eljárás
- images
- synthesising
- ike
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 239000002253 acid Substances 0.000 title description 5
- 150000003839 salts Chemical class 0.000 title description 4
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title description 2
- 229960003825 ivabradine Drugs 0.000 title description 2
- HJTHVTHXHHFXMJ-UHFFFAOYSA-N 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile Chemical compound C1=C(OC)C(OC)=CC2=C1C(C#N)C2 HJTHVTHXHHFXMJ-UHFFFAOYSA-N 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229910001369 Brass Inorganic materials 0.000 claims 1
- WCXDHFDTOYPNIE-UHFFFAOYSA-N acetamiprid Chemical compound N#CN=C(C)N(C)CC1=CC=C(Cl)N=C1 WCXDHFDTOYPNIE-UHFFFAOYSA-N 0.000 claims 1
- 239000010951 brass Substances 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/06—One of the condensed rings being a six-membered aromatic ring the other ring being four-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Mim iOD K)R. SYNTÍifdfsiNG 3.4-D! MB ΓΗΟΧΥB!CY('L<)í4.2.0j()C1M-1,3/ 1 lUDNSi-'Z-CARBONCmií J' AND USB TÖR SYNTH!'RISING ! VABRADINK AND TI ÍR ADDED SAL.1S THEREOF Wil Η Λ HMRMACWUCALLY
ACCEPTABLE ACID
The present invention relates to a proeess for the synthesis of i|4 JJlJoNp" I s3D-C!jpéR^öa^sal!rfte of lómitilá (If: \Ji l] © s'--" VOM« ·/
N and to the application thereof in the synthesis of tvahradtne and addition salts thereof with a |datitiacetmeaHy acceptable acttf
The compound ol lommla (I) obtained by the process of the invention A useful m the synthesis of i vabradine of formula t Πρ OMe
rlTl . W ......v /-™\ }.......°m Y il W s......../ ....... 0 or 4iS^Ö;]iöciU“ i. ^ aminolpropy i} -7*8-dimetltn<i y-! 3,4 J tetrahydrO"2//“3“hett/ay.epi O“2*0«es· of audita >e .mU:··. í heron vdth a phnrcoaeoutieaHy m.ccptable acid. and ol hydra tea thereof.
Kahntdhte ami addition suits thereof with a pharmaceutically ueceptabie odd. and mote especially the hydrochloride thereof Itnve sery valuable pharmacologies! anti therapeutic properties, especiall> hradyeardic properties. which {coder those corn pounds useful Itt the treatment or prevention t>f various elinica) conditions at myoea;rdisl pf bspnla, stich as angina peetoiiSj snyncardtal hithrcíttsn and apöefátgá rhythrn disordépv as w#i ha Ift wo« pathologies invotohig fhytko 4hmá%m>. especially supraventricular rhythm disosdess, und in heun failure Ί he preparation arai therapeutic use of ivabradine and addition salts thereof with a pharmaceutically aeeeptehls aekli. hud inore especinUy the hydrochloride- thereof, have been described in huropean patent bP 0 534 859.
That patent dcsenbes the preparation of ivabradine starting front 04 dtmftht»xyhiCYC}o|4.2.0)οο^·τ I ^-tnenew-earbonkrile of formula (I):
(1} which Iseoovertod into the compound o! formula till);
(HO which is resol ved to yield dmcdOspoand of ibiiMda (IV):
(tv) which is reacted with the compound of formula (V):
(V) to yield the eomposntd offtaiostla (Víg
(VI) she eatulym: hydrogenation of nhh:h yields: ivabrauine. which is thets converted ima hr hydrochloride, in- view öf MiéJíKiusfrial value of svubrudhu? and salts thereof it was imperative to find an effective process allma-ing the compound of formula «!} to be obtained m a good yield.
Application WO dÖl lilSI 62S desedhes the preparation of Che éaPipbttád of ihnmda (f) by intrarmdeetslar cyelisation of l-í2«bromO“4}5“dhnetho'sr^heoy:|:)* pmpm:te~.tiityi!e try tits presetted of bthita-n diefh|bamide or liihhnn diisopropykmMe.
The present invention relates to a process fór tie sjmthestl of' the eothpoahd of tonnida t.1}:
(!) eharecterised in that the compound of formula (VII);
tVh) is sobjeeted to the -action of l^is0Cyanontethylsulph«nyl}-4“TuethyibensseM·
flpsMlC:! !« tie presence of a base in e» oi'gp«c solvent or a mixture of otgeale solvents ts> yield the dontpohoh of tbnpola (IT h'K* íifuoüm üi S-shmc>\mom<dhylsulphonylM-meihyihen2ene preferably used to '.i.iií) Olit tUe COnVíUSíOn <U 11ti; Compound Ot ÍOrmiíia (VII) tO ΙΟ-ΎΠ tbc COmpOUdd öf feldúl» (!) is from 2 to 5 equivalents. .•"sn'ifiig the oases ihat may he used to carry out the conversion of the compound· oS lortmaa t v (I? to torm the compound ol formula i I h there tnay be menthonod,. without implying any limitation, organic hoses of the aikoxlde type such a$ potassium }ert~ rmio.xide, sodium ror/dxuoxule, potassium e?hoxkk\ sodium «dhoxidc, potassium; methnxide and sodium met hősidé. ihe ease preiemoly nscct to varr} on; me conversion of the compound of lormuia |Vt() to form the compound of formula (Π is potassium me^btdoxlde.. /Among toe organic solvents that may he used to carry ont the conversion of the compound of lomtula (Vli) to form the compound of formula (I), there may he ttiérniooed, without implying any limitation,, alcohols such as methanol, ethanol· tsopropuooh /«TMxuiannl, ietraimlrofuran, ethylene glycol and dimethyl suiphoxide. s he organic solvent used to cans out the conversion of the compound of formula (YU i to toon the conspunnd of formula (I) may also he composed >:d a mixture of two solvents from among the afore-mentioned organic solvents. ihe solvent preferably used to carry out the conversion of the compound of formula (VII) to torm the compound ©1 tormula-fl)',¾. of {pífftihydtdíhían and methanol !he conversion oi the compound oi iurtMla (¥11) hr. .form the compound of formula il) is preferably carried run at a temperature from -20CC m 5Q°C. ihe present invention relates also in a process tor the synthesis of the compound ol tormum (I) starting from she compound oi formula (VHk characterised in that said compound oi iormula (Yll) is prepared starting from the corn pound ol formula fVUI );
.(VEi) which is mm&MM-ÍMé a (I5C):
(£X) whemtp. E ffipvgssnls a (dXWhOatkyi grpip.
In the presence óin 1Jo!hdke>syeihene, therein she aikoxy groups have írom I to 4 carbon atoms, and un organt «metallic compound in an organic solvent, which is converted into the eomfxmmJ of lonMda (ΥΙΓρ
(vtn by a hydrolysis rgaeboig which is convened into the product of formula (1):
it) in aceprdáiiee with the process described hereinbefore.
The I .i-dialkoxyetheoe preferably used to carry out the conversion oi the compound ot formula (VIlh to toon ;hu compound of fonnuia (JX) is I,I-diethoxyethene.
The Mwurst psid;to -páöry: bhitte eottvefston of the eomfxrottif of fóomttó; (Vili.) fo forth tllcs eofhpetmd dí SsSsÉ (IX) lé: fern ()J tó 5 eputvakmis.
Among the organometulliv compounds that may he used to cam out the conversion of the compound of formula i Vffi) to form the compound of formula fIXh there may he tnemioned, without implying any hmhatmn, mbutyituhlum, v-butyfhthhnn. r-bulyliifhium, plumy Ihthium ínul is*^r&pylndtgnésium.eMndde*
The organoruetallh: compound preferably used to carry nut the conversion of the compound of formula (Vilit to form (he compound of formula (IX t is β~ Imiyiíúhmm,
The amount of mhutyliithiuro preferably used to carry out the conversion or the compound of formula (VIII) to fonts the compound of formula (DO is front i to 3 epiuvuiems.
Among the organic solehnts that may be used to carry out the conversion of the contpound of formula tVfllj to. form the compound of formula (LX), there may be mentioned, without impfyprg atry limitation, toluene^ fhtinhydrufemrn dlcltiommethápe: ártó chlprebeuaeM,
The srdveni preferably used to cany out the conversion ot the eompuostd of fpmtuia (Vili t to form the compound of fonottja t IX ) is toluene. "The conversion of the compound of formula fVilit to form the compound of funnuiu (IX) is preferably carried out at a temperature from "2CPC to IMPC2 1'he hydrolysis reaction performed on the compound of formula (IX) tu form the compound of tormuUs tVlit may be carried or it in an organoatuseous acidic medium composed of a mistun.·: * of an organic solvent such as teirnhydrofnran, ethyl acetate, toluene or diehloromefham* and » m abí<! suchás hydmbhlcrlb sddöN le 12H) io excess.
Tbc íbllám«;g Examples iJtusUute the invention,
The melting points were measured using a capillary melting point apparatus of the Buchi B-545 Melling point type, •fho· $4MMI specter aré:r«®0ft$eá sna 8Ar apparatus m 400 MB* for Ok? prolan spectra and at 100 ΜΗ* lor the carbon .spectra.
The chemical shifts ti>) arc expressed in rcrrr.cs oh ppm maenad standard: I MS).
The following abbreviations base been used to describe tire peaks, single! (sg do chi oi Big doublet of doublets {dd)t triplet (A. gcadroplot (qk mnlhpler hoc
Iiy;i!ÍJ&Ercsja?msís ntdpl m.p.: melting point I'l l I d teoahydrolurac
TmMIC; I -tisocyanomeThylstdpkm v 1)-4nenethy Ibeos&ne.
Preparation A: 1.2 1M!>roroo- To áimeihoxyhenaane 16,16 g of l.^;HlteMhpj?jfb'etósénb -(11 7 mtnoi) are shoex! atiHC; In CCdly (126 mL), 1X2 enL of dlhróndM (2.2 eq; XST4 irnneld 41J 3 §) disaoIvMln €.04:05 mL) am added dropwise (50 min! whilst monmning she temperature {Ο-Μ'ΤΜ [fit an outiéi which hubbies into a solution of Na.><.'0} in order to neutralise dtc hydrobrnmh, acid which forms], A iter stirring tor 2 bouts at tr:C, the reaction mixture is then poured onto a mÍKüue of water Hct·; am) the organic phase is washed with aqueous .10% NaHSO* solution and then os id aqueous 10% N’aOH solution. .Alter evaporation and drying, 13.42 g of a white solid corresponding to the title product are obtained.
Vidd ··· 07*« sn,p: 92-ETC illlMS ICIXdl: d ===7,06 ts: 211): 3.56 (s: 614), 1'X N'MIi iCDChj: d - 140; 115.9: 114.7; 56.2. jErtpa ration B; I i 1 -Oietteyetfef»#·
The equipment set-up Is as fbllavss; a 5(MpI flask provided with a dlstllfetlep set (column -20 cm; iondeftSét -20 cm, distillation tliartadroefer), 2itg of 2-hrotno/U~ dieihoxyethane (1(0.25 mmol) arc quickly added (I minute) n> potassium ten'' hutuKide (102 mmek 11.,4 g) cooled in uu ice hath Very dense white smoke is lormed, When the reaction ts complete (5-10 nunutes). the reaction mixture is heated to l2tM30;X' fhot-pinte reading), and the ten-htdamd generated during the reaction is distilled otY at atmospheric pressure When ait she lert-heUmol has bee a distilled off, a water-jet pomp is connected to the distillation set. !« this way, the. expected product is distilled otT hi. vtmm in a law seconds, &.§: g of a eolourtess liquid containing traoes of terMniinnol are obtained,
Iliid-72% Ί{.NMji ((.ΤΧ,Ίρ; h - 3.7H iq; 4Ηκ .103 is; 2H); 1/25 U; 6Hs.
Example It 7/}s.|>pq|u>^y''3,d'-diraethoxybicyidtqdX,ipsaia -13,5--krieue 2.5S g of 13'dihromo'd,5-dimeihoxybenzene (S.o2 nunol; 2 eq) and 500 tug of 1,1-dicthnxyethene (431 rnmnl; I eo|) in 25 mh of toluene are stirred at 0"(.: under argon. 3.5 ml, of «-butyllithium 02.5M in hexane, 8.62 mmol; 2 eq) ate added dropwise at (f"C. When the addition is complete, the reaction mixture is stirred tor 22 hours at ambient temperature. The reaction mixture is then hydrolysed and extracted 3 times with ethyl acetate. The organic phases ere dried and evaporated, and the crude product Is pari/ted by column ehromaiogntphy over silica gel (eluant', heptane'ethyl acetate 70/10/ There are obtained 333 mg of a yellow oil which crystallises at ambient tMopcrotum,
Yield -31% 111 NME (COOO: § - 6.86 (s; 111), 6.72 (s; ill); 334 (s; #1); 3.72 at; 4H); 3.30 (s; 211): 1.25 (t; fdl). ÍMÉ. 2; 3,4-Dí s»eü»>xybicydo[4.2.0 joeis-1 337τ1*η·-7-οη£ (1.7¾ % flJI menői) b stirred síi a mixture of ITHvwafcr (6.Ί) at. ambtent temperature, SIS mg of un aqucouo 1 IN 1 Ül sokason (1 Λ eg. 7.7 mrnoij are then added. The reaction mixture is stirred sor 2 honra ambient temperature. Water is added to SacHIran too extractions with ethyl acetate (2--3¾) *nf.l The organic phases are dried roe?· MgSO.s and then subjected to drying- l itere are obtained KOI g rd the title product irt the form of a pey: powder, jl.NMR íCPCu): 7.07 is; 7:1 it6.82 (s: 1H); 3.00 3H>; 3.87 (s; 5! 1). nC NMR. (CDCIV 185.8. 155.* 151.4; 146.2: 08 7; 105.6; 102.1 56 4; 56.1; 51 0.
IB&" 146:>C
Example 3; 3eí"ölnmUHfxybicyehíj4.L0fuct8--Md5-dmne--7~e8riíO»itríí<? Λ solution of I'osVHC (03>K g. 4.08 mmol, 2.3 eq) ht THE (3 ml.) is poured, over 20 iMadiéN idio á sedation of potasaltaBdeN'-beloxide (1,22 g; Ki# romol; 6 eqj in 11 if (7.5 mil stirred at tl'C under nitrogen. Then 2 00 n.L os'ntethastol are added t<> the mixture and stirring is maintained lor 30 minutes at (f'C, In parallel 3,4-- (1132 gí 2.17 hirnoi ! égi lithium bromide (0.19 g, 2.17 rnmoi, 1 eq? and TMF (2.5 mi.,} are loaded into a second three-necked flask, .after coo lag to (r"C under nitrogen. Ore solution of TosMlC arai potassium rwr-butoxide is transferred to the reaction mixture. .After returning to ambient temperature, the solution Is heated to TOY.' arid stirred for 16 hours at that temperature The mixture is then hydrolysed wuh a solution rd I IN 11C1 (0 ? ml , 7,73 mmol* in water (2 ml.). Alter eutporatmg off She (T1F under reduced pressure, the product is extracted with 5 mi. td'dichloromeihane. The organic phase is washed twice with 2X5 no. of water before being dried, 'the crude product is purified by coiu cun chromatography mer si boa gel using the binary mixture gestpe 75/25 to obtain the title product in tire form of a c rca no colon red powder.
Yield548-¾ tCDCEr 06 (si 11!κ i>.6K |s; IN); 4,i4 írn: Ili); λ 83 (s; 6H); 3.59-3.41 (m; 214}. ÍtelMÍ (C3DCk|: 151,4: 1¾¾ ! 44.2: 129.9; 119,9: 106.1; 56.2; 35.5; 2241
Exatnpk- 4: díOHnuthtrxY-'Orm'tkyiideych^OdlIncinO.'kOrk’ítOstmkto Based őrs IIIs 0 5.34 352 &&D.J.' 3,d43in5en5oxybicyelol4,2.ü]octa-l .3.>"trien-?"«minc hydrochloride 3 I 2 mi <>5a malar soha ion oí horune completed with ΠΙΕ ara added dropOw\ and whslsi sürdmj M imbieht témperahimno a Mliiilon of 26 g of d^dlóiothöxvfetoyete" [4.3.0joí.ta~1.3.Ü-nneííO-'earhiíndrde ht 250 ml. of Ilii· and led in contact for T2 hoars, 20(s mL óf étkmöl. arothm «ddetl am$ -storing Is carried nut for I ho:»·. 100 mi, ot 5.5N t ΚΊ hí ether a-re added drop-wise. 2?.? g of the expected product are obtained.
Vidd -= 90% md>: - 20X1'
Step 2: Ethyl (3 0''dlviXdh:0\yb!r:yolo|4,.?..01oepv-E>a5--tnen'?--yl}vndaamnte 1.5 ml., oi ethyl ehloroformate arc perused into a suspension of 3.4 g ot'she compound obtained is: Step 1 at 4,5 ml. of tricthytarthue and 50 nth. of dldiknomcdtauc, The whole is stirred overnight at ambient temperature anti then washed with water and IN hydrochloric acid. Drying is carried out and the solvent is evaporated off to dryness, 5.2 g of ass oil corresponding us the expected product are obtained.
Vidd - K0% 5w|l3; 3.4 - f dlmeth* wy-d-methylhu.· ytiof 4.2.0 jocta -1.5.5 -trien-d-astd ae 3.2 g of the compound obtained itt Step 2 dissolved in 30 snl, of Til!' are added to a Ipspenstop of 0.9 g of EiAiEid 1ft 20 ml, of T14F. This whole is ryfhrsdd: lor :1 boot lit hdPdtds add litert hydrolysed using thh mt df water: abddlJ ml, δΟΙΜ sodtism hydroxide solution amf finally, 2J ml,· of water. The mineral salts are .then ÍHiéred off and rinsed. with Tilly and then the filtrateobtained Is evaporated to dryness, 2,3: g of the expected: eornpound are obtained,
Yiek) === 92%
Example 3; {7S>~3«4-Di»*M&ö«f*:^t»íéi&^IMís^eI»|4i2ve|#ct»<í'!:^lí§*fri^^«t«.l»«:
Based on HP 0 534 859
The amine obtained te Example: 4 Is reacted wltlx an epelmdlar ampupl of fd! camphomulphonie acid in ethanol. .After evaporating off the solvent in vacuo, the salt Is seer¥SCafIbsed itrat from ethyl aectate and than fiam: acetonitrile orbit the mrget enanliorner is obtained with an optical purity of rnore than 99% feveloaied .fey ΉΡΙ.Γ on a Chunked' Of> column's. E sample hr 3"f3'-|{|{?S)~fM~Blmethox\bkyd»|4,2dl)9€ia*‘13,S“ifk»-7'yl}~ m ei hv S } {met hyt gt m ina \ propyl boxy- 1,3-d i hy drok11 "3 - Is e ncaeep i n ~2 - ope
Based on O' is 514 05V A solution of the ids eamphorsulphonate salt obtained in Example 5 in ethyl acetate is brought to haste pH using sodium hydroxide and then the organic phase is separated oil. washed, dried out Nu-jSO.; and evaporated. A mixture composed of 5.6 g of potassium eetfeooate. 2.2· g of the above amine in 10Ö ntk of acetone and 4 g of bensavepinA'-one is then refluxed for IB hours.
The solvent is evaporated otV m vacuo, and the residue is taken up in ethyl acetate ami then extraeted with YN hydoKhlone acid
The aqueous phase separated oiT hr feonght to basic pH using sodium hydroxide and is then exiraetyd with ethyl acetate. Alter washing until neutral and drying over MgVO.;, evaporation hi vacuo is carried out to obtain 4.5 g ofAo oik which is purified on a silica eehtmb using a ihtxfofi of d!o|t|ofometica;c'mekumol f 90/111} ax' eloaM.
Yiekl::: 64% txxnmple ?; 3~f 3-j f |{7S)*3$4»Dii»e*hexy I I|«* 8H,0tyÍ|{methyi|ams«o)pröpyi}~?J8-dimeih«xy4vM3Aeíyabyíírö-2ll“3·' benr.&iiepbi ^"«nc Eased on b.h 0 514 8$<> 5 g of die compound obtained in Example t> in 50 ml. of glacial acetic acid are hydrogenated in a Parr apparatus under a hydrogntr pressure of C9 bar at ambient temper;ante for 14 hours in the presence of 1 g of 101« palladium hydroxide. The catalyst is Eltéred off. the solvent is evaporated off and then the dry residue is taken up in voiku and. ethyl aeeiate. I he ingunk phase is dried ote.i anhydrous magnesium sulphate, concentration hi vacuo is eurrted out and then die residue is purified on a silica column using a mixture of nldrlorumethanedneihanol Ehv'5) as eluant, After recrystaHisation iVom ethyl acetate, 2 goftbo expected compound ate obtained.
Ire hi -ho it
ntjy ' iOi HU'V
Claims (6)
- 8M>séskm igheygysttok1Iliiké (I) képMk vegyiketÍÖ οΙΜΗίί&ϊΡΡ:*. avval jeik-ssaeavo, hogy ( VH) képiéi;-! vegyelek;;(VS) alávstsüsfe fíksMlC): kstssikskk egy Mtí$ jélépléídbétv «gy s-am-es ddé&seeben, így kap|«k a:(S) képletS: vsgyülélet:
- 2. Az i. Igéeypoísí «.arioh ekáíás. sxxsí jelieseeeve, hegy a (VH) képlelk vegye let (!) képlete vegygletls '!$$£<$ áfc^íiás&rd· 1)¾½¾¾2. Az ? s&gy 2 igéeypoot sísnok kijárás, assail jelkueesve, hogy a (¥ü> képleté veg>ttl«í (!> képkiö vegyükaté íttítéaS ákhakkkska h&sx’kd; bash; baburo-im'buiatieléí, násrksot'i'íe'e-btbeoolét, káHun'í-crsanolás, eáttkeo-íí&sxoiik kklkao-metsaokk ésaittriuevmelSLoelás kbxtt; van ki válásai va 4. Λ 2. igéoypo-e sserhsü ekóhh, ássál Jdiemexve, hogy a (VH) képlett) vagyaiét fi) képlett! ypgyáMkí töstéoö síalakMwPa hasxahk báxis káHtort-fm'· buts&nol&t.
- 5. Az 1-4. sgéovpotooh béreielylke sseo/ttl eljárási »ex*8 Jeiieises.viy hogy a (VH) képkiü vegyiket (I) képklp vegysletté iöriéttS étetékllsskkt tuísgohl) ssetves pklóaéét' leéttseek etaooL iMgröpasök íprée^atssipi, teisshttkbttgihy otHép'fHkhi és dkobiihkiíttl ibsM vagy &jp. oldásttetek kiMtí kettő keveréke kögltt vett kMfsssttya. 6. Λ?. 5. igénypont s&ínsei eiktrá-e aesal jellemeevo, hogy & (VH) képlett) vegyiket ()} képlete vegyökih; terttínö öialakiiá-dn) has evéé ss-ove;; okiósi&'r tae;kobmí\;r«o és metaool keveréke
- 7. Ax 1-6. Igéoypovook hájo-ehlke ?áattí$U eijásas. sasai jelieosee.ve, bogy a (VII) képkiü vegylllpt (.1) képk'O's vgavó letté Ktnéeó asekiklttlttki -20'(. - .Hré. hbsoé-sóhieieii vpgee.seL k. Aa s. jgéoypoei saetstttl eljárás, ami jéilettteséé, hogy á (Vll| képMS vegyttlPkt (Vili) képkttl veg>b leiből kbódulva allitluk elő.(Vitt) ísOíCisv· éttuakOttok t!X) képkia vegvpkíseρκ) ábéí Xjetpikése (ΟΜ,ΑΜίΜοροη. I.!'dssikoxfctés'K amelyben ex ibsosresopossak 1--4 sséoskíníesak, és -így sxerves 1¾ süvegeibe · )etekll!étas egy sxerVes sldisxéébkh.. amdy I \X} képiek! veg> ök'td sxenes.-v;ges ssvss káKégbéPÍVll) klplsbl vegyíSlghlbíésöllgállök. % és I- Ig-ééypöst ss|tö$ eyiris, ggKbt jejlkdisye, hegy g (Vlij) képletS vegybkt (IXj képisák t^s$h&Ít:tP-vtíyfcoxt«í«ft ax XáMiekíXioiie. 5 0 A V igénypons szerinti eljárás, arad jdkieíexvf, hogy « IS'Ül) képiek! :Y§gy&M 0X$. ké^loti. vlgybieeé íéirtérso átaiskitásáre hasxíiáiii J-dietoxidln «i«fmyiségft 0-S-S ekvivalens. Η. Λ 8“íí> igcnyponiok bármely ike szene: s eljárás, sexei jsik'oíose, hogy a i VIHj hépleUs vegyibe! í l X; képiek! Y«ey«krHe röHéno ,Pakd·; kásán* immák szerves fénvvegék:· «'bsitiUítmm* a~bk?iiHtiym, AlshIIIitiubg féhj 1.1 Misé) Is IMkiöpIlmlgnéxIom^hlwsd kopp! vm kiváissstvs.
- 12, Λ II. igénypont szerinti eljárás, axxsl jellemmé, hogy a íVill) képiéi! Vhgybtéi fiX) képiéül vegyöleíté történd áMakhásání használtsserves Íésnyegyltlíb «áosííllltiitm, Ϊ5.Λ 12. sgényponí szerint! dját&k a*x*S |e!le«urxve, hogy a (VUh képlete wgvblei (IX) képiek! vegyök'tíé történd átalakítisáro hasasait «-hötíllfttu*» mennyisége K> ekvivalens. M A ihB. Igloygpsrkík: bármelyike széniül epráe, *m! jellemezve, hogy a iYIO) képiek; vegyibe; (IX) képjétb VégyhlsM !Ss#nb étrbákMsáza. hásxkájl: szerves oldószer löktől. tetnihidroiorárt, dfcklörroetán és blbrhéüsöi késmii vm kiváláséivá., !5. Λ M. ígés-ypoor szerinti eysrás. azzal jdlmexve, kegy a fVUS) képiek! vegyibe!; (I) képiéül yegySiéitl iöriéph áiá1ábl|ásim hgszrkpt szerves plálsxlr iplhof, Iá- Ah i--.1.-5 < sgékypöhipk bánkélyika szén bt! é páráé, gézéi jébekiéévét hegy g (kbllj kégiétk vegyiket ( IX) kép leik végálbeké iöriéitl álalákítákk
- 17. Eljárás ivabraáine, esíssk <-WV>g*d.h;n6 sgia és másíkjai séMllMsspg amelyek sokfes (Vil)lké|>tó v«gydMek8& K sgássyposd »Karl;é! «yirásssl (ö MplelÖ kéa||t«mékk# éts!»k!!|«k snap! ;í:í: (!) képkíS te^fméköi^alsmd^emé-átaJstöjiá,·.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1354504A FR3005658B1 (fr) | 2013-05-17 | 2013-05-17 | "procede de synthese du 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable" |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE031370T2 true HUE031370T2 (hu) | 2017-07-28 |
Family
ID=48874340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14168559A HUE031370T2 (hu) | 2013-05-17 | 2014-05-16 | Eljárás 3,4-dimetoxibiciklo[4.2.0]okta-l,3,5-trién-7-karbonitril elõállítására, ennek alkalmazása ivabradine szintézisében, továbbá ennek gyógyszerészetileg elfogadható savval alkotott addíciós sója |
Country Status (36)
Country | Link |
---|---|
US (1) | US8859763B1 (hu) |
EP (1) | EP2803659B1 (hu) |
JP (1) | JP5916793B2 (hu) |
KR (1) | KR101625128B1 (hu) |
CN (1) | CN104163777B (hu) |
AR (1) | AR096324A1 (hu) |
AU (1) | AU2014202434B2 (hu) |
BR (1) | BR102014011633A2 (hu) |
CA (1) | CA2851960C (hu) |
CY (1) | CY1120482T1 (hu) |
DK (1) | DK2803659T3 (hu) |
EA (1) | EA026224B1 (hu) |
ES (1) | ES2621804T3 (hu) |
FR (1) | FR3005658B1 (hu) |
GE (1) | GEP20156416B (hu) |
HK (2) | HK1200028A1 (hu) |
HR (1) | HRP20170394T1 (hu) |
HU (1) | HUE031370T2 (hu) |
IN (1) | IN2014DE01203A (hu) |
JO (1) | JO3276B1 (hu) |
LT (1) | LT2803659T (hu) |
MD (1) | MD4443C1 (hu) |
ME (1) | ME02636B (hu) |
MX (1) | MX345278B (hu) |
NZ (1) | NZ624774A (hu) |
PL (1) | PL2803659T3 (hu) |
PT (1) | PT2803659T (hu) |
RS (1) | RS55917B1 (hu) |
SA (1) | SA114350532B1 (hu) |
SG (1) | SG10201402034PA (hu) |
SI (1) | SI2803659T1 (hu) |
TW (1) | TWI500596B (hu) |
UA (1) | UA116337C2 (hu) |
UY (1) | UY35561A (hu) |
WO (1) | WO2014184501A1 (hu) |
ZA (1) | ZA201403543B (hu) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3005658B1 (fr) * | 2013-05-17 | 2015-04-24 | Servier Lab | "procede de synthese du 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable" |
EP3101010A1 (en) | 2015-06-03 | 2016-12-07 | Urquima S.A. | New method for the preparation of highly pure ivabradine base and salts thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
FR2870537A1 (fr) * | 2004-05-19 | 2005-11-25 | Servier Lab | Nouveau procede de synthese du (1s)-4,5-dimethoxy-1-(methyl aminomethyl-)-benzocyclobutane et de ses sels d'addition, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2933975B1 (fr) * | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
JP5435127B2 (ja) | 2010-05-06 | 2014-03-05 | 株式会社島津製作所 | 材料試験機 |
HUP1000245A2 (en) * | 2010-05-07 | 2011-11-28 | Richter Gedeon Nyrt | Industrial process for the production ivabradin salts |
FR3005658B1 (fr) * | 2013-05-17 | 2015-04-24 | Servier Lab | "procede de synthese du 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable" |
-
2013
- 2013-05-17 FR FR1354504A patent/FR3005658B1/fr active Active
-
2014
- 2014-05-02 IN IN1203DE2014 patent/IN2014DE01203A/en unknown
- 2014-05-05 CN CN201410185124.1A patent/CN104163777B/zh not_active Expired - Fee Related
- 2014-05-05 AU AU2014202434A patent/AU2014202434B2/en not_active Ceased
- 2014-05-05 SG SG10201402034PA patent/SG10201402034PA/en unknown
- 2014-05-06 JO JOP/2014/0157A patent/JO3276B1/ar active
- 2014-05-08 MD MDA20140048A patent/MD4443C1/ro not_active IP Right Cessation
- 2014-05-09 NZ NZ624774A patent/NZ624774A/en not_active IP Right Cessation
- 2014-05-12 UY UY0001035561A patent/UY35561A/es not_active Application Discontinuation
- 2014-05-12 CA CA2851960A patent/CA2851960C/fr not_active Expired - Fee Related
- 2014-05-14 TW TW103117037A patent/TWI500596B/zh not_active IP Right Cessation
- 2014-05-14 GE GEAP201413468A patent/GEP20156416B/en unknown
- 2014-05-14 BR BRBR102014011633-8A patent/BR102014011633A2/pt not_active IP Right Cessation
- 2014-05-14 SA SA114350532A patent/SA114350532B1/ar unknown
- 2014-05-14 UA UAA201405094A patent/UA116337C2/uk unknown
- 2014-05-14 US US14/277,151 patent/US8859763B1/en not_active Expired - Fee Related
- 2014-05-14 MX MX2014005822A patent/MX345278B/es active IP Right Grant
- 2014-05-15 ZA ZA2014/03543A patent/ZA201403543B/en unknown
- 2014-05-16 DK DK14168559.4T patent/DK2803659T3/da active
- 2014-05-16 EP EP14168559.4A patent/EP2803659B1/fr active Active
- 2014-05-16 SI SI201430179A patent/SI2803659T1/sl unknown
- 2014-05-16 AR ARP140101965A patent/AR096324A1/es unknown
- 2014-05-16 ME MEP-2017-64A patent/ME02636B/me unknown
- 2014-05-16 PL PL14168559T patent/PL2803659T3/pl unknown
- 2014-05-16 KR KR1020140059053A patent/KR101625128B1/ko not_active Expired - Fee Related
- 2014-05-16 JP JP2014101963A patent/JP5916793B2/ja active Active
- 2014-05-16 ES ES14168559.4T patent/ES2621804T3/es active Active
- 2014-05-16 RS RS20170308A patent/RS55917B1/sr unknown
- 2014-05-16 PT PT141685594T patent/PT2803659T/pt unknown
- 2014-05-16 LT LTEP14168559.4T patent/LT2803659T/lt unknown
- 2014-05-16 HU HUE14168559A patent/HUE031370T2/hu unknown
- 2014-05-16 EA EA201400473A patent/EA026224B1/ru not_active IP Right Cessation
- 2014-05-16 WO PCT/FR2014/051140 patent/WO2014184501A1/fr active Application Filing
- 2014-12-31 HK HK14113135.3A patent/HK1200028A1/zh not_active IP Right Cessation
-
2015
- 2015-01-14 HK HK15100395.4A patent/HK1199872A1/xx not_active IP Right Cessation
-
2017
- 2017-03-09 HR HRP20170394TT patent/HRP20170394T1/hr unknown
- 2017-04-03 CY CY20171100398T patent/CY1120482T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100917698B1 (ko) | 레트로졸의 제조를 위한 개선된 방법 | |
HUE033497T2 (hu) | Eljárás szapropterin-dihidroklorid elõállítására | |
CN110615744B (zh) | 一种布瓦西坦中间体及其制备方法 | |
CN102471302B (zh) | 决奈达隆及其盐的制备方法 | |
KR101726468B1 (ko) | 네비보롤의 제조방법 | |
HUE031370T2 (hu) | Eljárás 3,4-dimetoxibiciklo[4.2.0]okta-l,3,5-trién-7-karbonitril elõállítására, ennek alkalmazása ivabradine szintézisében, továbbá ennek gyógyszerészetileg elfogadható savval alkotott addíciós sója | |
CN104140410A (zh) | 鲁比前列酮的制备方法 | |
EP3077354B1 (fr) | Nouveau procede de synthese de l'agomelatine | |
KR20100118747A (ko) | 사포그릴레이트 염산염의 개선된 제조방법 | |
EP1907371B1 (en) | Process for preparing 2-methoxycarbonylmethyl-6,6-dimethyl-2- tetrahydropyran carboxylic acid | |
EP2799426B1 (en) | New process for the synthesis of aminaphtone | |
CN111132955A (zh) | 用于生产β-春烯的新方法 | |
TWI855165B (zh) | 製備(r)-4-胺基茚烷及其對應醯胺的方法 | |
CN110078660B (zh) | 2-氯-5-甲基吡啶的制备方法 | |
KR20230160787A (ko) | 바이오틴의 제조 방법 및 바이오틴의 l-라이신염 및그 제조 방법 | |
DE69802176T2 (de) | ein neues verfahren für die Herstellung von 3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide | |
WO2019015545A1 (zh) | 海兰地嗪制备方法 | |
CN105884706A (zh) | 新利司他高效的合成方法 | |
AU2017283772B2 (en) | Process for producing lamivudine and emtricitabine | |
TWI516483B (zh) | 決奈達隆及其鹽的製備方法 | |
CN111556861A (zh) | 茉莉酸酯化合物的制备方法 | |
RU2483055C1 (ru) | Способ получения 1,5-бис(2-гидроксифенокси)-3-оксапентана моногидрата | |
CN111065641A (zh) | 柠檬酸伊沙佐米的制备方法 | |
US9745281B2 (en) | Method for the synthesis of 4-(heterocycloalkyl)-benzene-1,3,-diol compounds | |
KR100911720B1 (ko) | 결정형 염산 사포그릴레이트의 제조방법 |